(Total Views: 676)
Posted On: 10/20/2020 8:11:30 AM
Post# of 148902
B Patterson PR. excerpt
Maraviroc, an oral medication, will be administered for seven days. Blood will be collected at Day 0, 3, 7 and 14. IncellDx is performing a Maraviroc-specific CCR5 Receptor Occupancy assay, their IncellKINE RUO Cytokine Storm quantification panel, immune profiling with T-cell exhaustion and macrophage polarization as well as SARS-CoV-2 plasma viral load (pVL) .
Bruce Patterson MD, CEO of IncellDx commented that "Since the beginning of the COVID-19 pandemic, IncellDx has led the way in defining the role of CCR5 antagonism in diagnosis and treatment of COVID-19. We are excited to collaborate in the study of Maraviroc's potential as a therapeutic for COVID-19.
https://www.prnewswire.com/news-releases/ince...portal_CAP
Maraviroc, an oral medication, will be administered for seven days. Blood will be collected at Day 0, 3, 7 and 14. IncellDx is performing a Maraviroc-specific CCR5 Receptor Occupancy assay, their IncellKINE RUO Cytokine Storm quantification panel, immune profiling with T-cell exhaustion and macrophage polarization as well as SARS-CoV-2 plasma viral load (pVL) .
Bruce Patterson MD, CEO of IncellDx commented that "Since the beginning of the COVID-19 pandemic, IncellDx has led the way in defining the role of CCR5 antagonism in diagnosis and treatment of COVID-19. We are excited to collaborate in the study of Maraviroc's potential as a therapeutic for COVID-19.
https://www.prnewswire.com/news-releases/ince...portal_CAP
(1)
(1)Scroll down for more posts ▼
